COMMUNIQUÉS West-GlobeNewswire

Positive interim data shows Roche’s sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN)
23/09/2026
In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential Sefaxersen inhibits [...]
OSE Immunotherapeutics annonce la présentation des principaux résultats de l'étude de Phase 2 Combi-TED de Tedopi® dans le cancer du poumon non à petites cellules au Congrès 2026 de l’ESMO
23/09/2026
Nantes, France, 23 septembre 2026 – 7h30 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie [...]
OSE Immunotherapeutics Announces Presentation of Combi-TED Phase 2 Topline Results of Tedopi® in Non-Small Cell Lung Cancer at the ESMO 2026 Meeting
23/09/2026
Nantes, France, September 23, 2026 – 7:30am CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and [...]
The Hemp Doctor's Cannabis Consumer Behavior Survey: Average Buyer Is 45
23/09/2026
A 10,214-response survey from The Hemp Doctor finds its customers are older, more self-directed, and more cannabinoid-literate than most of the industry has assumed MOORESVILLE, N.C., Sept. 23, 2026 (GLOBE NEWSWIRE) -- [...]
Anaconda Biomed Secures $56 Million Financing from New and Existing Investors
23/09/2026
Proceeds used to complete ongoing ATHENA pivotal IDE study, continue product development, and secure global regulatory approvals for neurovascular portfolio BARCELONA, Spain and MARIN, Calif., Sept. 23, 2026 (GLOBE [...]
Scarlet Therapeutics Secures DARPA Agreement to Develop Adaptive Smart Red Blood Cells
23/09/2026
Agreement, worth up to $14 million, validates the potential of pioneering red blood cell technology platform BRISTOL, United Kingdom, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Scarlet Therapeutics Ltd (‘Scarlet’), a biotech [...]
Actimed Therapeutics Completes Recruitment for PROACT Phase 2a Study Evaluating S-pindolol benzoate (ACM 001.1) in Obese Adults During and After Semaglutide Therapy
23/09/2026
London, UK – 23 rd September 2026. Actimed Therapeutics Ltd (“Actimed”) has successfully completed patient recruitment for the PROACT Study (Protocol ACM 001 2024 01 CT; NCT07101939), a two part, Phase 2a, randomised, [...]
Engitix appoints Sonia Quaratino, MD, PhD as EVP Chief Medical Officer as its ECM pipeline moves toward clinical development
23/09/2026
LONDON, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Engitix Ltd., a biotechnology company pioneering extracellular matrix (ECM)-based discovery platforms to transform drug development in oncology, fibrosis and fibro‑inflammatory [...]
Boehringer Ingelheim and AWARE launch new Stop Rabies project in Zimbabwe to help protect dogs and communities
23/09/2026
Rabies remains one of the world’s deadliest yet preventable zoonotic diseases, highlighting the need for sustained prevention efforts. Through a new multi-year collaboration, Boehringer Ingelheim and AWARE are expanding [...]
Change in Roche’s Board of Directors
23/09/2026
Roche announced today that the Board of Directors of Roche Holding Ltd has approved to propose Dr. Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board of Directors at Roche’s Annual General [...]
InnovAge Announces Pricing of Secondary Offering of Common Stock by Selling Stockholders
23/09/2026
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
IN8bio to Present at Sidoti Small-Cap Virtual Conference
22/09/2026
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers for cancer and autoimmune [...]
Acquisition of Own Shares
22/09/2026
Mechelen, Belgium; September 22, 2026, 22.01 CET; regulated information Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") [...]
InnovAge Announces Launch of Proposed Secondary Offering of Common Stock by Selling Stockholders
22/09/2026
DENVER, Sept. 22, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible [...]
Biomea Fusion Announces Proposed Public Offering of Securities
22/09/2026
SAN CARLOS, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, announced today that it has commenced an underwritten public offering [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
22/09/2026
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 22 sept. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Voting Rights and Shares Capital of the Company
22/09/2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Sept. 22, 2026 (GLOBE NEWSWIRE [...]
Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change
22/09/2026
TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“ Helus ” or the “ Company ”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel [...]
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
22/09/2026
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced that its Board of Directors has authorized a cash dividend to [...]

Pages